QOLP-37. MOOD DISTURBANCE IN PATIENTS WITH CENTRAL NERVOUS SYSTEM (CNS) TUMORS DURING THE COVID-19 PANDEMIC

Lily Polskin; Valentina Pillai; Elizabeth Vera; Alvina Acquaye; Nicole Briceno; Anna Choi; Alexa Christ; Ewa Grajkowska; Varna Jammula; Heather Leeper; Jason Levine; Matthew Lindsley; Jennifer Reyes; Kayla Roche; James Rogers; Michael Timmer; Lisa Boris; Eric Burton; Nicole Lollo; Marissa Panzer; Marta Penas-Prado; Brett Theeler; Jing Wu; Mark Gilbert; Terri Armstrong; Amanda King

doi:10.1093/neuonc/noab196.757

QOLP-37. MOOD DISTURBANCE IN PATIENTS WITH CENTRAL NERVOUS SYSTEM (CNS) TUMORS DURING THE COVID-19 PANDEMIC

Lily Polskin, Valentina Pillai, Elizabeth Vera, Alvina Acquaye, Nicole Briceno, Anna Choi, Alexa Christ, Ewa Grajkowska, Varna Jammula, Heather Leeper, Jason Levine, Matthew Lindsley, Jennifer Reyes, Kayla Roche, James Rogers, Michael Timmer, Lisa Boris, Eric Burton, Nicole Lollo, Marissa PanzerMarta Penas-Prado, Brett Theeler, Jing Wu, Mark Gilbert, Terri Armstrong, Amanda King

Neurology

Research output: Contribution to journal › Article › peer-review

Abstract

Abstract BACKGROUND

Primary CNS tumors are associated with uncertainty likely contributing to mood disturbance that is common throughout the disease trajectory. The intersection of the COVID-19 pandemic with a CNS tumor diagnosis may further impact the anxiety/depression experienced in this population. This study assessed key anxiety/depression symptoms in patients with CNS tumors prior to and during the COVID year.

METHODS

Patient reported outcomes (PROs), including the PROMIS Anxiety and Depression Short Forms and EQ-5D-3L, were collected at the time of clinical or telehealth evaluation from the COVID year (March 2020-February 2021) and were compared to assessments through February 2020 (a NOB-normative sample), reflecting what we would typically see in our regular clinic evaluations.

RESULTS

The COVID sample (N = 178) was primarily White (82%), male (55%), median age of 45 (range 18–79), and KPS ³ 90 (50%). The majority had high grade (70%) brain (83%) tumors with ³ 1 prior recurrence (60%) and 25% were on active treatment. Visits were primarily conducted via telehealth (64%) and 20% had progression at assessment. Compared to the NOB-normative sample, patients reported significantly higher depression scores (moderate-severe, 17% vs. 12%, p < 0.05), but not anxiety (18% vs. 16%). Eleven percent reported both moderate-severe anxiety and depressive symptoms (8% pre-COVID). Overall health assessed by the EQ-5D-3L was similar to the normative sample in all dimensions, apart from impact of moderate/extreme mood disturbance, which was more prevalent in the COVID year (53% vs. 43%, p < 0.05%).

CONCLUSION

Patients with CNS tumors are at risk for significant symptoms of depression and anxiety; this risk was heightened during the COVID year. Further evaluation of clinical factors associated with risk are underway. These findings highlight the need for assessments and interventions that can be administered via telehealth to address the mental health needs of this vulnerable population.

Radiobiology

Original language	American English
Pages (from-to)	vi191-vi191
Journal	Neuro-Oncology
Volume	23
Issue number	Supplement_6
DOIs	https://doi.org/10.1093/neuonc/noab196.757
State	Published - Dec 2021

Access to Document

10.1093/neuonc/noab196.757

Cite this

Polskin, L., Pillai, V., Vera, E., Acquaye, A., Briceno, N., Choi, A., Christ, A., Grajkowska, E., Jammula, V., Leeper, H., Levine, J., Lindsley, M., Reyes, J., Roche, K., Rogers, J., Timmer, M., Boris, L., Burton, E., Lollo, N., ... King, A. (2021). QOLP-37. MOOD DISTURBANCE IN PATIENTS WITH CENTRAL NERVOUS SYSTEM (CNS) TUMORS DURING THE COVID-19 PANDEMIC. Neuro-Oncology, 23(Supplement_6), vi191-vi191. https://doi.org/10.1093/neuonc/noab196.757

@article{1528fa57a48a4a26a912ba67d5f8a1a9,

title = "QOLP-37. MOOD DISTURBANCE IN PATIENTS WITH CENTRAL NERVOUS SYSTEM (CNS) TUMORS DURING THE COVID-19 PANDEMIC",

abstract = "Abstract BACKGROUND Primary CNS tumors are associated with uncertainty likely contributing to mood disturbance that is common throughout the disease trajectory. The intersection of the COVID-19 pandemic with a CNS tumor diagnosis may further impact the anxiety/depression experienced in this population. This study assessed key anxiety/depression symptoms in patients with CNS tumors prior to and during the COVID year. METHODS Patient reported outcomes (PROs), including the PROMIS Anxiety and Depression Short Forms and EQ-5D-3L, were collected at the time of clinical or telehealth evaluation from the COVID year (March 2020-February 2021) and were compared to assessments through February 2020 (a NOB-normative sample), reflecting what we would typically see in our regular clinic evaluations. RESULTS The COVID sample (N = 178) was primarily White (82%), male (55%), median age of 45 (range 18–79), and KPS ³ 90 (50%). The majority had high grade (70%) brain (83%) tumors with ³ 1 prior recurrence (60%) and 25% were on active treatment. Visits were primarily conducted via telehealth (64%) and 20% had progression at assessment. Compared to the NOB-normative sample, patients reported significantly higher depression scores (moderate-severe, 17% vs. 12%, p < 0.05), but not anxiety (18% vs. 16%). Eleven percent reported both moderate-severe anxiety and depressive symptoms (8% pre-COVID). Overall health assessed by the EQ-5D-3L was similar to the normative sample in all dimensions, apart from impact of moderate/extreme mood disturbance, which was more prevalent in the COVID year (53% vs. 43%, p < 0.05%). CONCLUSION Patients with CNS tumors are at risk for significant symptoms of depression and anxiety; this risk was heightened during the COVID year. Further evaluation of clinical factors associated with risk are underway. These findings highlight the need for assessments and interventions that can be administered via telehealth to address the mental health needs of this vulnerable population. Radiobiology ",

author = "Lily Polskin and Valentina Pillai and Elizabeth Vera and Alvina Acquaye and Nicole Briceno and Anna Choi and Alexa Christ and Ewa Grajkowska and Varna Jammula and Heather Leeper and Jason Levine and Matthew Lindsley and Jennifer Reyes and Kayla Roche and James Rogers and Michael Timmer and Lisa Boris and Eric Burton and Nicole Lollo and Marissa Panzer and Marta Penas-Prado and Brett Theeler and Jing Wu and Mark Gilbert and Terri Armstrong and Amanda King",

year = "2021",

month = dec,

doi = "10.1093/neuonc/noab196.757",

language = "American English",

volume = "23",

pages = "vi191--vi191",

journal = "Neuro-Oncology",

issn = "1522-8517",

number = "Supplement_6",

}

Polskin, L, Pillai, V, Vera, E, Acquaye, A, Briceno, N, Choi, A, Christ, A, Grajkowska, E, Jammula, V, Leeper, H, Levine, J, Lindsley, M, Reyes, J, Roche, K, Rogers, J, Timmer, M, Boris, L, Burton, E, Lollo, N, Panzer, M, Penas-Prado, M, Theeler, B, Wu, J, Gilbert, M, Armstrong, T & King, A 2021, 'QOLP-37. MOOD DISTURBANCE IN PATIENTS WITH CENTRAL NERVOUS SYSTEM (CNS) TUMORS DURING THE COVID-19 PANDEMIC', Neuro-Oncology, vol. 23, no. Supplement_6, pp. vi191-vi191. https://doi.org/10.1093/neuonc/noab196.757

TY - JOUR

T1 - QOLP-37. MOOD DISTURBANCE IN PATIENTS WITH CENTRAL NERVOUS SYSTEM (CNS) TUMORS DURING THE COVID-19 PANDEMIC

AU - Polskin, Lily

AU - Pillai, Valentina

AU - Vera, Elizabeth

AU - Acquaye, Alvina

AU - Briceno, Nicole

AU - Choi, Anna

AU - Christ, Alexa

AU - Grajkowska, Ewa

AU - Jammula, Varna

AU - Leeper, Heather

AU - Levine, Jason

AU - Lindsley, Matthew

AU - Reyes, Jennifer

AU - Roche, Kayla

AU - Rogers, James

AU - Timmer, Michael

AU - Boris, Lisa

AU - Burton, Eric

AU - Lollo, Nicole

AU - Panzer, Marissa

AU - Penas-Prado, Marta

AU - Theeler, Brett

AU - Wu, Jing

AU - Gilbert, Mark

AU - Armstrong, Terri

AU - King, Amanda

PY - 2021/12

Y1 - 2021/12

N2 - Abstract BACKGROUND Primary CNS tumors are associated with uncertainty likely contributing to mood disturbance that is common throughout the disease trajectory. The intersection of the COVID-19 pandemic with a CNS tumor diagnosis may further impact the anxiety/depression experienced in this population. This study assessed key anxiety/depression symptoms in patients with CNS tumors prior to and during the COVID year. METHODS Patient reported outcomes (PROs), including the PROMIS Anxiety and Depression Short Forms and EQ-5D-3L, were collected at the time of clinical or telehealth evaluation from the COVID year (March 2020-February 2021) and were compared to assessments through February 2020 (a NOB-normative sample), reflecting what we would typically see in our regular clinic evaluations. RESULTS The COVID sample (N = 178) was primarily White (82%), male (55%), median age of 45 (range 18–79), and KPS ³ 90 (50%). The majority had high grade (70%) brain (83%) tumors with ³ 1 prior recurrence (60%) and 25% were on active treatment. Visits were primarily conducted via telehealth (64%) and 20% had progression at assessment. Compared to the NOB-normative sample, patients reported significantly higher depression scores (moderate-severe, 17% vs. 12%, p < 0.05), but not anxiety (18% vs. 16%). Eleven percent reported both moderate-severe anxiety and depressive symptoms (8% pre-COVID). Overall health assessed by the EQ-5D-3L was similar to the normative sample in all dimensions, apart from impact of moderate/extreme mood disturbance, which was more prevalent in the COVID year (53% vs. 43%, p < 0.05%). CONCLUSION Patients with CNS tumors are at risk for significant symptoms of depression and anxiety; this risk was heightened during the COVID year. Further evaluation of clinical factors associated with risk are underway. These findings highlight the need for assessments and interventions that can be administered via telehealth to address the mental health needs of this vulnerable population. Radiobiology

AB - Abstract BACKGROUND Primary CNS tumors are associated with uncertainty likely contributing to mood disturbance that is common throughout the disease trajectory. The intersection of the COVID-19 pandemic with a CNS tumor diagnosis may further impact the anxiety/depression experienced in this population. This study assessed key anxiety/depression symptoms in patients with CNS tumors prior to and during the COVID year. METHODS Patient reported outcomes (PROs), including the PROMIS Anxiety and Depression Short Forms and EQ-5D-3L, were collected at the time of clinical or telehealth evaluation from the COVID year (March 2020-February 2021) and were compared to assessments through February 2020 (a NOB-normative sample), reflecting what we would typically see in our regular clinic evaluations. RESULTS The COVID sample (N = 178) was primarily White (82%), male (55%), median age of 45 (range 18–79), and KPS ³ 90 (50%). The majority had high grade (70%) brain (83%) tumors with ³ 1 prior recurrence (60%) and 25% were on active treatment. Visits were primarily conducted via telehealth (64%) and 20% had progression at assessment. Compared to the NOB-normative sample, patients reported significantly higher depression scores (moderate-severe, 17% vs. 12%, p < 0.05), but not anxiety (18% vs. 16%). Eleven percent reported both moderate-severe anxiety and depressive symptoms (8% pre-COVID). Overall health assessed by the EQ-5D-3L was similar to the normative sample in all dimensions, apart from impact of moderate/extreme mood disturbance, which was more prevalent in the COVID year (53% vs. 43%, p < 0.05%). CONCLUSION Patients with CNS tumors are at risk for significant symptoms of depression and anxiety; this risk was heightened during the COVID year. Further evaluation of clinical factors associated with risk are underway. These findings highlight the need for assessments and interventions that can be administered via telehealth to address the mental health needs of this vulnerable population. Radiobiology

UR - https://www.mendeley.com/catalogue/d867ab98-9b2a-3b17-b830-185d898a1f8b/

U2 - 10.1093/neuonc/noab196.757

DO - 10.1093/neuonc/noab196.757

M3 - Article

SN - 1522-8517

VL - 23

SP - vi191-vi191

JO - Neuro-Oncology

JF - Neuro-Oncology

IS - Supplement_6

ER -